抗肝纤维化药物研发进展  

Research progress in drugs for anti-hepatic fibrosis

作　　者：张文东 王瑞范 吴会敏 杨慧 王国成[3] ZHANG Wen-dong;WANG Rui-fan;WU Hui-min;YANG Hui;WANG Guo-cheng(College of Pharmacy, lnner Mongolia Medical University, Hohhot 010110, China;College of Pharmacy, China Pharmaceutical University, Nanjing 210009, China;Chemical Medicine R＆D Center, Tasly Academy, Tianjin Tasly HoMing Group Co., Ltd., Tianjin 300410, China)

机构地区：[1]内蒙古医科大学药学院,内蒙古呼和浩特010110 [2]中国药科大学药学院,江苏南京210009 [3]天士力控股集团有限公司研究院化学药品开发中心,天津300410

出　　处：《药学学报》2018年第5期667-675,共9页Acta Pharmaceutica Sinica

摘　　要：肝纤维化是由慢性肝损伤发展为肝硬化、肝癌的重要病理过程,目前临床上尚无有效治疗肝纤维化的化学药物,因此抗肝纤维化药物的研发仍是新药研发的热点。大多数在研药物的主要作用机制为抑制引起肝纤维化的各种因素,包括肝星状细胞活化增殖、炎症、氧化应激及细胞外基质生成等。本文在此分类基础上就相关靶点和药物进行简要梳理和分析,以期为抗肝纤维化药物的进一步研发提供参考。Hepatic fibrosis is an important pathological process in the development of liver cirrhosis and liver cancer from chronic liver damage. So far there is no effective chemical drug in clinic for treatment of hepatic fibrosis. Therefore, the research in anti-hepatic fibrosis drugs is a hot topic. For drugs currently under research and development, most of the mechanisms of action are related to inhibition of factors that could cause or deteriorate liver fibrosis, including activation and proliferation of hepatic stellate cells, inflammation, oxidative stress and production of extracellular matrix, et al. In this review, we briefly analyze targets and drugs related to the mechanisms mentioned above in order to provide a reference to the future research and development of anti-hepatic fibrosis drugs.

关 键 词：抗肝纤维化药物 肝纤维化 肝星状细胞 炎症 氧化应激 细胞外基质 

分 类 号：R966[医药卫生—药理学]